

Paroxysmal nocturnal haemoglobinuria – eculizumab or ravulizumab – continuing authority application

Online PBS Authorities



You do not need to complete this form if you use the **Online PBS Authorities** system.

For more information and how to access the **Online PBS Authorities** system, go to servicesaustralia.gov.au/hppbsauthorities

When to use this form

Use this form to apply for **continuing** PBS-subsidised eculizumab or ravulizumab for patients with paroxysmal nocturnal haemoglobinuria (PNH).

Important information

Continuing authority applications can be made using the **Online PBS Authorities** system or in writing and must include sufficient information to determine the patient's eligibility according to the PBS criteria.

Under no circumstances will phone approvals be granted for PNH **continuing** authority applications.

Complement 5 (C5) inhibitors are defined as eculizumab or ravulizumab.

The information in this form is correct at the time of publishing and may be subject to change.

Continuing treatment

This form is ONLY for **continuing** treatment.

Section 100 arrangements for eculizumab and ravulizumab

These items are available to a patient who is attending:

- an approved private hospital, **or**
- a public hospital

and is a:

- day admitted patient
- non-admitted patient, **or**
- patient on discharge.

These items are not available as a PBS benefit for in-patients of a public hospital.

The hospital name and provider number must be included in this authority form.

For more information

Go to servicesaustralia.gov.au/healthprofessionals

Paroxysmal nocturnal haemoglobinuria – eculizumab or ravulizumab – continuing authority application

Online PBS Authorities



You do not need to complete this form if you use the
Online PBS Authorities system.

Go to servicesaustralia.gov.au/hppbsauthorities

Patient's details

1 Medicare card number

Ref no.

or

Department of Veterans' Affairs card number

2 Family name

First given name

3 Date of birth (DD MM YYYY)

4 Patient's current weight

 kg

Prescriber's details

5 Prescriber number

6 Family name

First given name

7 Business phone number (including area code)

Alternative phone number (including area code)

Hospital details

8 Hospital name

This hospital is a:

☐ public hospital

☐ private hospital

9 Hospital provider number

Conditions and criteria

To qualify for PBS authority approval, the following conditions must be met.

10 The patient is being treated by a:

☐ haematologist

☐ non-specialist medical physician who has consulted a
haematologist

11 This application is for:

☐ the **first continuing** treatment with

☐ eculizumab ▶ **Go to 12**

or

☐ ravulizumab ▶ **Go to 13**

or

☐ **subsequent continuing** treatment with

☐ eculizumab ▶ **Go to 15**

or

☐ ravulizumab ▶ **Go to 16**

12 Has the patient received PBS-subsidised treatment with this
drug for this condition under the 'Initial', 'Balance of Supply',
or 'Grandfather' treatment criteria?

Yes ☐ ▶ **Go to 14**

No ☐

13 Has the patient received PBS-subsidised treatment with
this drug for this condition under the 'Initial' or 'Grandfather'
treatment restriction?

Yes ☐

No ☐



MCA0PB328 2506

14 Provide details of the following monitoring requirements

Test	Result	Date of test (DD MM YYYY)			
Haemoglobin (g/L)					
Platelets (x10 ⁹ /L)					
White Cell Count (x10 ⁹ /L)					
Reticulocytes (x10 ⁹ /L)					
Neutrophils (x10 ⁹ /L)					
Granulocyte clone size (%)					
Lactate Dehydrogenase (LDH)					
Upper limit of normal (ULN) for LDH as quoted by the reporting laboratory					
LDH : ULN ratio (in figures, rounded to one decimal place)					

► **Go to 18**

15 Has the patient previously received PBS-subsidised treatment with this drug for this condition under the 'First Continuing Treatment' or 'Switch' criteria?

Yes ☐ ► **Go to 17**

No ☐

16 Has the patient previously received PBS-subsidised treatment with this drug for this condition under the 'First Continuing Treatment' or 'Return' criteria?

Yes ☐

No ☐

17 Has the patient experienced clinical improvement or a stabilisation of the condition as a result of treatment with this drug?

Yes ☐

No ☐

18 Is this treatment in combination with another C5 inhibitor or pegcetacoplan?

Yes ☐

No ☐

Checklist

19  The relevant attachments need to be provided with this form.

☐ Details of the proposed prescription(s).

Privacy notice

20 Personal information is protected by law (including the *Privacy Act 1988*) and is collected by Services Australia for the purposes of assessing and processing this authority application. Personal information may be used by Services Australia, or given to other parties where the individual has agreed to this, or where it is required or authorised by law (including for the purpose of research or conducting investigations).

More information about the way in which Services Australia manages personal information, including our privacy policy, can be found at servicesaustralia.gov.au/privacypolicy

Prescriber's declaration

You do not need to **sign** the declaration if you complete this form using Adobe Acrobat Reader and return this form through Health Professional Online Services (HPOS) at servicesaustralia.gov.au/hpos

21 I declare that:

- I am aware that this patient must meet the criteria listed in the current Schedule of Pharmaceutical Benefits to be eligible for this medicine
- I have informed the patient that their personal information (including health information) will be disclosed to Services Australia for the purposes of assessing and processing this authority application
- I have provided details of the proposed prescription(s) and the relevant attachments as specified in the Pharmaceutical Benefits Scheme restriction
- the information I have provided in this form is complete and correct.

I understand that:

- giving false or misleading information is a serious offence.

☐ I have read, understood and agree to the above.

Date (DD MM YYYY) (you **must** date this declaration)

--	--	--	--	--	--

Prescriber's signature (**only** required if returning by post)



Returning this form

Return this form, details of the proposed prescription(s) and any relevant attachments:

- **online** (no signature required), upload through HPOS at servicesaustralia.gov.au/hpos
- **or**
- by post (signature required) to
Services Australia
Complex Drugs Programs
Reply Paid 9826
HOBART TAS 7001